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Polymeric microparticles with covalently attached biotin are proposed as versatile targeting vehicles for drug
delivery. The proposed microparticles made of 85/15 poly (lactic-co-glycolic acid) (PLGA) will have biotin available
on the outside of the particle for the further attachment with an avidin group. Taking advantage of biotin’s high
affinity for avidin, and avidin’s well-known chemistry, the particle has the potential to be easily coated with a variety
of targeting moieties. This paper focuses on the design and resulting effect of adding biotin to PLGA microparticles
using an integrated experimental and modeling approach. A fluorescent-tagged avidin (488-streptavidin) was used
to confirm the presence and bioavailability of biotin on the outside of the particles. For the purpose of this study,
bovine serum albumin (BSA) was used as a model therapeutic drug. Microparticles were created using two different
types of polyvinyl alcohol 88 and 98 mol% hydrolyzed, which were then analyzed for their size, morphology, and
encapsulation capacity of BSA. Release studies performed in vitro confirmed the slow release of the BSA over a
28-day period. Based on these release profiles, a release kinetics model was used to further quantify the effect of
biotinylation of PLGA microparticles on their release characteristics by quantitatively extracting the effective drug
diffusivity and drug desorption rate from the release profiles. It was found that the biotinylation of the PLGA
microparticles slowed down both the drug desorption and drug diffusion process, which confirmed that
biotinylated PLGA microparticles can be used for controlled drug release. The presented technology, as well as the
proposed integrated experimental and modeling approach, forms a solid foundation for future studies using a
cell-specific ligand that can be attached to avidin and incorporated onto the microparticles for targeted delivery.Background
Polymeric microparticles have been widely researched
for their ability to serve as controlled drug delivery
vehicles Brannon-Peppas (1995; Cleland 1997; Shive and
Anderson 1997). The main goals of these vehicles are to
provide improved drug disposition Putney (1998), pro-
tection from metabolic degradation Dziubla et al. (2005),
and increased circulation time Putney (1998). The new
goal in these designs, however, is to take them a step
further and incorporate a method for targeting specific
cells Brannon-Peppas and Blanchette (2004; Fung and
Saltzman 1997). It is well known that the side effects of* Correspondence: noelle.comolli@villanova.edu
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in any medium, provided the original work is pdrugs stem from drug interactions in non-targeted cells,
such as severe anemia experienced by cancer patients
Balkwill (2004; Pegram et al. 1997) and those on antiviral
medications (such as HIV and HCV treatments) Sayce
et al. (2010). A method to target these cells directly
would not only increase the potency of the drugs, but
also drastically improve the quality of life for the
patients on these treatments.
While biodegradable polymeric microparticles have
been investigated for the controlled release of anticancer
therapeutics Fung and Saltzman (1997; Datta et al. 2006;
Folger et al. 2006), and to a limited extent, for antiviral
drugs Datta et al. (2006), the challenge of effective
targeting still remains. There are few markers that are
specific only to tumor cells, but rather most are simplys is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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(2004; Pegram et al. 1997). The challenge of identifying
a sole marker to a tumor cell or virus is one that biologist
and biochemist are still researching. With an evolving field
of possible targets and ligands, the challenge for the engi-
neers then is to create a robust mechanism for incorpor-
ation of these new ligands to a polymeric delivery vehicle.
Polymers most commonly used for microparticle drug
release include poly(lactic acid) (PLA), poly(glycolic acid)
(PGA) and their copolymer poly(lactic-co-glycolic acid)
(PLGA) Anderson and Shive (1997; Cao and Shoichet
1998; Panyam et al. 2003). In order to obtain the desired
release of the drug for the specific delivery, the amount of
glycolic acid can be increased to increase the degradation
rate, and therefore speed the release time. The PLGA used
was an 85/15 mixture of lactic to glycolic acid. The
biodegradation of PLGA occurs through a homogenous
hydrolytic chain cleavage mechanism, in which both the
surface and the bulk polymer degrade at similar rates
Anderson and Shive (1997). The breakdown of PLGA is
purely through hydrolysis and does not need the assistance
of an enzyme Muthu (2009).
In order to target specific cell lines, a robust targeting
strategy is proposed. Taking advantage of the affinity of
biotin with avidin, a strong non-covalent bond can easily
be created by adding biotin to the surface of the PLGA.
Biotin strongly binds to avidin and streptavidin via a
combination of van der Waals and hydrophobic interac-
tions. In perfect conditions, a single molecule of avidin
would bind to four molecules of biotin. This high affinity
makes it possible to have site-specific microparticles that
have predetermined antibodies attached to the avidin
Datta et al. (2006; Moro et al. 1997). This platform
would allow for various avidin-antibody complexes to be
connected to the biotin microparticle in order to make a
multi-faceted drug delivery system. Since this takes
advantage of the same mechanism many biochemical
assays use, the chemistry of avidin attachment to an
antibody, or antibody fragment, is already well known
Moro et al. (1997; Diamandis and Christopoulos 1991;
Kocbek et al. 2007). This platform allows both targeted
delivery (via the PEG-biotin-avidin), as well as controlled
release, and biochemical protection of the drug during
the delivery via the PLGA.
Previous research has shown the potential in using
polymeric microparticles with a similar linkage but using
the reverse order (avidin linked to the polymer) Park
et al. (2011). The proposed method is used as a simpler
method for attaching the conjugate covalently to the
polymer while controlling the length of the ‘tethering’
arm spacing the conjugate and the polymer. The
proposed tethering arm in this case will be a short chain
polyethylene glycol (PEG) that can be increased or
decreased in length as needed. The attachment ofbiotin-PEG to a nanoparticle of PLGA was previously
done using a more complex chemistry by Weiss et al.,
for the proposed use of rapid fluorescent tagging of the
nanoparticles Weiss et al. (2007). Although these particles
were evaluated for their ability to attach to biotin, the
release of drug was not investigated.
In order to better understand the effect that biotin has
on the polymeric microparticle, along with the usual
in vitro characterization (drug encapsulation, morphology,
release rates), release kinetics will further be modeled
from experimental data to extract important quantitative
information that is essential for the comparative study of
the proposed PLGA microparticles. Specifically, drug
release from polymeric microparticles undergoes two
main phases: (1) the induction (or burst) phase in which
an initial burst of protein release is observed due to the
desorption of proteins from the surface of mesopores
within microparticles and the outer surface of microparti-
cles; (2) the diffusion phase in which the macromolecular
drug contained in the occlusions of microparticles diffuse
through the pores that are formed during the hydration,
degradation and erosion of microparticles. Accordingly,
the drug desorption rate determines the dynamics of the
initial drug burst, while the diffusion rate determines the
subsequent drug release. In this work, a theoretical model
of macromolecular drug release presented by Batycky
et al. (1997), as shown in Equation (1), is used to quantify
drug desorption rate and effective drug diffusivity from
drug release profiles. Thus, the effect of polyvinyl alcohol
(PVA) surfactants as well as the attachment of biotin to
the polymeric microparticles on the drug release process
can be quantified.
The mass fraction of released drug, frelease, is determined
by the following equation:












where φburstd is the mass fraction of drug involved in the
burst phase, kd is the drug desorption rate constant, Dd is
the effective drug diffusivity, td is the drug induction time
that allows for the coalescence of micropores and the pas-
sage of the macromolecular drug out from the occlusions
through the coalescing micropores in microparticles, and r0
is the initial microparticle radius. The first term of Equation
1 represents the burst phase during which the proteins
from the surface of mesopores within microparticles and
the outer surface of microparticles are released and during
which the micropores within microparticles coalesce for
the further release of the encapsulated drug. Following the
burst phase is the diffusion phase that is described by the
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The time evolution of released mass, frelease predicted from
Equation 1, will be compared to the experimental released
profile. The values of the parameters that are important for
characterizing drug released process, including φburstd , kd,
and td, are then determined by fitting the model given in
Equation 1 to the experimental data. Therefore, Equation 1
is used as a soft-sensor in this work for quantitatively moni-
toring the drug desorption rate and effective drug diffusivity
that cannot be directly determined from the release profiles
by eye inspection. These parameters can be used as quanti-
tative criteria for the selection of PLGA microparticles for
drug delivery. The primary goal of this paper is to evaluate
the effect of the biotinylation of the PLGA microparticles
on their morphology and release characteristics.
Materials and methods
Materials
PLGA was purchased from SurModics, located in
Birmingham, AL, USA. The EZ-LinkWTFPA-PEG3-Biotin,
488-streptavidin, potassium nitrate, and micro bicinchoni-
nic acid (BCA) protein assay kit were all obtained from
Thermo Fisher Scientific (Waltham, MA, USA). A biotin
quantification kit was bought from Pierce Biotechnology
(Rockford, IL, USA). The ethyl acetate, dichloromethane
(DCM), and dimethyl sulfoxide (DMSO) used in the
preparation of the microparticle, as well as bovine serum
albumin (BSA) and phosphate buffered solution (PBS) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). The
sodium azide was purchased from Acros Organics (Geel,
Belgium). The PVA was brought from Polysciences, Inc.
(Warrington, PA, USA).
Biotinylation of PLGA
The PLGA and DMSO were combined in a 10:1 ratio and
vortexed until the PLGA dissolved. EZ-Link TFPA-PEG3-
Biotin was attached to PLGA in a 20-fold molar excess of
biotin (10 mg/mL in DMSO). The amount of biotin was
determined using the following equation:
Vbiotin ¼ 1; 000 mPLGAMWbiotinMWPLGAMbiotinCbiotin ð2Þ
where mPLGA is the mass of PLGA; MWbiotin and
MWPLGA are the molecular weight of biotin and PLGA,
respectively; Mbiotin is the mole of excess of biotin; Cbiotin
is the concentration of biotin.
The mixture was then photoactivated using UV light for
30 min. After quenching the reaction with approximately
15 mL of deionized (DI) water, the solution was then
centrifuged using the Sorvall Legend RT Plus Centrifuge
(Thermo Scientific) at 14,000 rpm for approximately
7 h at room temperature. The samples were stored at
4°C until use.Quantification of biotin
A biotin quantification kit was used to compare the
absorbance of a sample to a positive control, biotinylated
horseradish peroxidase (HRP). To begin the analysis, a
PLGA-biotin pellet was dissolved in ethyl acetate. 40-
hydrocyazobenzene-2-carboxylic acid (HABA)-avidin
was then added to both the control and sample. The
plate was shaken for approximately 60 s, and the
displaced HABA was measured using a BioTek ELx800
UV/Vis microplate reader at a wavelength of 490 nm.
The ratio of biotin to PLGA was determined using the
recorded absorbance values. All results are presented as the
average of triplicate samples with the standard deviation.
PLGA microparticle synthesis
The water-in-oil-in-water method is a common emulsion
technique that was performed at room temperature.
Briefly, 150 μL of phosphate buffered saline (pH 7.4) with
varying amounts of dissolved protein was added to 2 mL of
the oil phase (10 mg/mL PLGA in ethyl acetate), and the
emulsion was created by adding energy to the solution by
homogenizing for 60 s. The primary emulsion was
stabilized with the addition of bovine serum albumin
(1 mg/mL) to the internal aqueous phase. The primary
emulsion was then quickly added to 300 mL of an external
aqueous phase (5 wt.% PVA). The emulsion was stabilized
through stirring at 500 rpm and the presence of the PVA
(either 88 or 98 mol% hydrolyzed). The microparticles
hardened while stirring overnight and the ethyl alcohol
was evaporated. The microparticles were collected via
centrifugation at 14,000 rpm for 90 min. Afterwards, the
supernatant was removed and the microparticles were
resuspended in DI water. The microparticles were washed
two more times and centrifuged at 14,000 rpm at respect-
ively 90 and 30 min. The microparticles were allowed to
dry and either used immediately or kept at 4°C until use.
Fluorescent imaging
PLGA-biotin and non-biotinylated PLGA particles were
analyzed under fluorescent imaging. Approximately 5 mg
of particles were suspended in 1 mL of DI water in an
amber microcentrifuge tube. A 5 μL of 488-streptavidin
was added to the solution and it was stored in a dark loca-
tion for at least 90 min. The tube was then centrifuged at
13,300 rpm for 15 min at room temperature. Microparticles
were then washed, removing the supernatant, and the pellet
was resuspended in a small amount of DI water. The
sample was centrifuged at 13,300 rpm for 15 min and the
supernatant was removed. The sample was then placed on
a glass slide with a cover slip and viewed on a Leica DM
2000 microscope (Leica Microsystems, USA). Images
were captured and viewed using a Q imaging Retiga-SRV
camera and QCapture Pro 6.0 software (Q Imaging, Surrey,
British Columbia, Canada).
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Protein encapsulation was evaluated by dissolving a
known weight of particles (5 mg) in 2 mL DCM. The
dissolved particles were mixed with 3 mL of DI water
and the solvent-water mixture was shaken overnight at
200 rpm. This provided sufficient time for the protein to
be extracted into the water phase. A sample was taken
from the water phase and the concentration was found
using a BCA protein assay (used per manufacturer’s
instructions). The BCA assay is a colorimetric assay
based on bicinchoninic acid and measures the total protein
content in a sample. Negative controls of the particle made
with no protein present at all were also performed to
ensure that the presence of the degraded lactic acid did not
affect the concentration readings.
In vitro release of model drugs
Protein release from the microparticles was evaluated
in vitro using a known mass of dried microparticles in
30 mL of PBS (with 0.01% NaN3 to prevent bacterial
growth). All studies were set so sink conditions would
be maintained, specifically, that at no point would the
maximum released concentration of protein be greater
than 10% the saturation limit for that protein in PBS.
Samples of the release medium were removed at designated
times using a sample probe with an inline 0.45-μm filter to
prevent removal of the microparticles during sampling.
Equal volumes of fresh PBS were back-flushed through the
filter to ensure a constant volume throughout the study as
well as to ensure that any microparticles trapped in the
sample probe would be flushed back into the sample
container. Samples were kept at -20°C until analysis. Con-
centrations were found using the BCA protein assay at 490
nm, per manufacturer’s instructions.
Particle morphology
Using completely dried microparticles, the size and surface
morphology of the particles were observed using the scan-
ning electron microscope. A fraction of the microparticle
was taken and placed on a small metal stage, fitted with
double-sided carbon tape. The sample was then coated. The
sample was placed in a Hitachi S-570 scanning electron
microscope (Hitachi America Ltd., Brisbane, CA, USA) for
observation under vacuum. The size and distribution of the
particles was determined. Using dissolved microparticles,
the size of the particle was observed using the Hitachi 7600
transmission electron microscope. Six microliters of the
sample was placed on a carbon graph and allowed to dry.
The dried sample was sputter coated with a conductive
metal and placed in the microscope for examination.
Particle size
Using completely dried microparticles, the size and
polydispersity of the particles were observed using theparticle size analyzer. A portion of the microparticle was
suspended in 4.5 mL of 10 mM of KNO3. The suspension
was approximately 10 mg to 4 mL. The sample was then
placed in a Brookhaven 90 plus particle size analyzer
(Brookhaven Instruments Corporation, Holtsville, NY,
USA) for examination. The KNO3 was used instead of
PBS since the salt solution was necessary to allow for the
laser scattering that is needed.Quantifying drug desorption rate constant and effective
drug diffusivity from drug release profiles
While the BSA release percentage can be determined
from the release profile directly, the release kinetics
parameters such as the effective diffusion rate and the
drug desorption cannot be directly determined by eye
inspection from experimental data. Thus, release kinetics
parameters such as drug desorption rate (kd) and effective
drug diffusivity
―
Dd in Equation 1 were estimated by fitting
frelease predicted by Equation 1 to experimental drug re-
lease profiles (‘In vitro release of model drugs’ section) via
the following procedure:
1. φburstd and td , which correspond to the mass and
time for drug release in the burst phase respectively,
were determined from the inflection point of drug
release profiles, as the inflection point indicates the
switch of drug release from the burst phase to the
diffusion phase.
2. kd and Dd were determined via a nonlinear least
squares approach, which can be represented by
Equation 3. This computation was performed by
minimizing an objective function consisting of the
sum of the squares over N measurements of the
differences between the experimental data frelease and
the model-predicted output frelease. MATLAB
(Mathworks Inc., Natick, MA, USA) routine fmincon








f^ release ið Þ  frelease ið Þ
h i2
subject to
frelease ¼ φburstd 1 ekdt











The first step in microparticle production was to
synthesize biotinylated PLGA. To do this, TFPA-PEG3-
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order to confirm the attachment of the biotin on the
polymer, a biotin quantification kit was used. The weight
of biotin in relation to polymer was calculated and found
to be approximately 0.87 ± 0.37. Once the polymer was
confirmed to have biotin, microparticles were made
using a water-in-oil-in-water (W/O/W) method. To
ensure that the biotin was available to avidin on the
outside of the polymer microparticle, a fluorescent assay
was performed. Microparticles were combined with
streptavidin that was tagged with a green fluorophore
(Alexa 488; Life Technologies Corporation, Carlsbad,
CA, USA). After incubation, the microparticles were
collected, washed, and immediately viewed using a Leica
DM 2000 microscope. Presence of green fluorophore
(white in Figure 1, Alexa 488 + biotin-PLGA microparti-
cles) around the microparticle indicates that the biotin
not only attached to the perimeter, but also was still bio-
logically available for the streptavidin post-microparticle
processing. A negative control (Figure 1, Alexa 488 +
PLGA microparticles), confirms that the streptavidin is
not merely sticking to the polymer surface, but rather to
the biotin available on the surface.
Once the microparticle synthesis viability was confirmed,
the size and polydispersity were confirmed using a Broo-
khaven 90 plus particle size analyzer (via dynamic light
scattering). Microparticles were made with and without
biotin, as well as with and without the model drug (BSA).
Microparticles were also made using two different types of
PVA (the surfactant for the secondary emulsion step, 88
and 98 mol% hydrolyzed) in an attempt to optimize the
microparticle synthesis. Analysis of the samples (Table 1)
found that the addition of biotin to the PLGA causes an in-
crease in particle size for both 88 and 98 mol% hydrolyzed
PVA. This trend is expected since the presence of the biotin
makes the polymer larger as well as more hydrophobic.Figure 1 Fluorescent imaging confirms presence of biotin on the out
the surface of the PLGA microparticles was confirmed by incubating biotin
several times prior to visualization under the fluorescent microscope. Left im
fluorophore (white) indicates the biotin was present and capable of attachThe biontinylated PLGA particle containing no BSA
created a smaller distribution in the molecular masses of
the samples. This could be a result of the biotin itself help-
ing to stabilize the emulsion. Interestingly, the addition
of BSA without biotin present increased the particle size;
however, the addition of BSA into the biotinylated PLGA
particles actually showed a decrease in size. This decrease
in size was unexpected but may indicate a specific reac-
tion of the BSA and biotin during the W/O/W emulsion
and may not be critical when using the actual cancer thera-
peutic drug. The particles were created using both 88 and
98 mol% PVA, and it was found that particles generated
from the 98 mol% PVA are larger than the particles made
from the 88 mol% PVA. The 98 mol% PVA is roughly ten
times larger than the 88 mol% PVA particles. The polydis-
persity of the 98 mol% PVA microparticles was larger than
the 88 mol% PVA microparticles as well, indicating that the
increase in hydrophilicity in the 98 mol% PVA did not pro-
vide an increased stabilizing effect on the emulsion as com-
pared to the 88 mol% PVA.
Microparticles were synthesized using either 88 or 98
mol% PVA as a surfactant as well as with and without the
biotin attached to the PLGA. The resulting microparticle
size and polydispersity were determined via dynamic light
scattering. Results are presented as the average of n = 4
samples ± standard deviation.
In order to evaluate the morphology of the microparti-
cles, both a Hitachi S-4800 scanning electron microscope
(SEM) and a Hitachi 7600 transmission electron micro-
scope (TEM) were used to view samples of the biotinylated
and plain PLGA microparticles. SEM and TEM images of
both 88 and 98 mol% PVA methods are shown in Figure 2.
The TEM and SEM images confirm that the addition of the
biotin to the PLGA does not change the spherical morph-
ology of the microparticles. The microparticles with and
without biotin do not have any morphological differencesside of microparticles. The presence and bioavailability of biotin on
ylated microparticles with streptavidin-488. The particles were washed
age, Alexa 488 + biotin-PLGA microparticles. The presence of the 488
ing the steptavidin. Right image, Alexa 488 + PLGA microparticles.








PLG no BSA (88) 7.81 ± 13.52 0.48 ± 0.55
PLGA BSA (88) 8.06 ± 23.12 0.36 ± 0.037
Biotin BSA (88) 1.83 ± 4.23 0.39 ± 0.18
Biotin no BSA (88) 21.24 ± 15.02 0.021 ± 0.015
PLGA No BSA (98) 21.99 ± 14.91 0.67 ± 0.39
PLGA BSA (98) 30.72 ± 49.99 0.50 ± 0.36
Biotin BSA (98) 16.47 ± 11.85 0.80 ± 0.36
Biotin No BSA (98) 37.97 ± 97.51 0.39 ± 0.52
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changes (with the exception of size) when changing from
88 to 98 mol% PVA during processing. The ability of the
microparticle to keep its spherical shape is an indication
that the microparticle morphology is not changed by the
addition of the biotin. The agglomeration seen in some of
the SEM is believed to be a result of the drying process for
imaging and is not expected when the microparticles are in
solution.Figure 2 Microparticle size and morphology. Biotinylated microparticles
resulting microparticles were imaged using a SEM (top images) as well as a
and size ranges determined via dynamic light scattering.Once the particle size and morphology was characte-
rized, the mass percentage of BSA encapsulated as well
as the encapsulation efficiency of the model drug was
determined (Table 2). It was found that for particles
made from 88 mol% PVA, the PLGA particles had a
slightly higher average encapsulation than the bioti-
nylated particles. On the other hand, when the PVA was
changed to 98 mol%, the average encapsulation per-
centage for the biotinylated particle was higher than
the PLGA particle. The 88 mol% PVA, however, had
similar encapsulation of BSA between the plain PLGA
and biotinylated PLGA microparticles. Although the 98
mol% hydrolyzed PVA may be a better surfactant, there
is no clear trend apparent for the effect of biotin on the
encapsulation of a drug; further optimization should be
done using the actual therapeutic. It was determined
that the 98 mol% PVA more effectively stabilized the
microparticle during hardening, allowing for the higher
encapsulation (shown in Table 2) of BSA. If the particle
can be successfully stabilized during the hardening step,
it should not swell and allow water in, or drug out.
If higher encapsulation corresponds to the larger size, since
more internal aqueous phase is retained, the microparticleswere synthesized using either 88 or 98 mol% PVA as a surfactant. The
TEM (bottom images). Images confirmed the spherical morphology










PLG (88) 4.12 3.21
Biotin (88) 3.30 1.78
PLGA (98) 3.02 4.35
Biotin (98) 12.26 15.57
Figure 3 BSA release from microparticles synthesized with 88
mol% PVA. BSA release from microparticles synthesized using 88
mol% PVA (with and without biotin) in vitro over a 28-day period.
Both the biotinylated and non-biotinylated microparticles controlled
the release of the BSA with a minimal initial burst. Samples were
quantified using the micro BCA and are presented as the average of
n = 4. Error bars indicate the standard deviation. No difference was
found between the two sets of microparticles release profiles.
Figure 4 BSA release from microparticles synthesized with 98
mol% PVA. BSA release from microparticles synthesized using 98
mol% PVA (with and without biotin) in vitro over a 28-day period.
Both the biotinylated and non-biotinylated microparticles controlled
the release of the BSA with a minimal initial burst, with no real
difference in their release profiles. Samples were quantified using
the micro BCA and are presented as the average of n = 4. Error bars
indicate the standard deviation.
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out during this phase is a common problem during har-
dening, since the osmotic pressure will readily drive mole-
cules through the oil phase (polymer in solvent) until it
fully hardens. This flux creates the largest challenge in
designing microparticle with a high drug loading.
Microparticles were synthesized using either 88 or 98
mol% PVA as a surfactant as well as with and without the
biotin attached to the PLGA. The resulting microparticle’s
loading of BSA was quantified dissolving the microparticle
and extracting the BSA which was quantified using a
micro BCA assay. The BSA loading is presented as both
the percentage of the particle mass that is BSA as well as
the percentage of the initial BSA that was actually loaded
into the microparticle.
Once the amount of drug encapsulated in each type of
microparticle was determined, the rate of release of the
model drug could be evaluated. In vitro release studies
were performed under sink condition in PBS at 37°C for
all four types of microparticles. Using a micro BCA
assay, the mass of BSA released was determined. The
cumulative percentage of BSA released over time was
calculated and is shown in Figures 3 and 4. It was
determined that the release of BSA from the biotinylated
and PLGA particle, made from 88 mol% PVA, followed
the same trend (Figure 3) over a 28-day period. This
indicates that the presence of biotin on the surface of
the microparticle does not alter the release characteris-
tics of the microparticles. The same result was found for
microparticles made using 98 mol% PVA (Figure 4). For
the 28-day period, approximately 80% of the model drug
is released for both biotinylated and non-biotinylated
microparticles. Comparing Figures 3 and 4, there is no
apparent effect of the change in surfactant on release, as
expected. The change in the surfactant should mainly
change the microparticles stability during formation,
leading to potential changes in morphology and encap-
sulation capacity.
In order to further quantify the effect of the biotinylation
of the PLGA microparticles on the drug release characteris-
tics, the effective drug diffusivity and drug desorption rate
that directly characterize the drug release process are
further determined from the release profiles. Specifically,the model given by Equation 1 is fitted to the release
profiles presented in Figures 3 and 4 via the approach
shown in ‘Quantifying drug desorption rate constant and
effective drug diffusivity from drug release profiles’ section.
The values of the parameters
―
Dd , kd, φ
burst
d and td in
Figure 5 Comparison of experimental data to BSA release profiles. Comparison of experimental data to BSA release profiles, predicted by
the model shown in Equation 1 with estimated parameters Dd , kd, ϕd
burst, and td. The RMSD values for microparticles PLGA-BSA (88 mol% PVA),
biotin-BSA (88 mol% PVA), PLGA-BSA (98 mol% PVA), and biotin-BSA (98 mol% PVA) are 2.68%, 4.05%, 2.37%, and 4.55%, respectively. Error bars
indicate the standard deviation.
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Figure 5, which shows that the drug release profiles
predicted by the estimated model fit the experimental data
well for all types of microparticles under investigation. In
particular, the predicted drug release profiles pass through
most error bars shown in the data. The root-mean-square
deviation of prediction (RMSD) for microparticles PLGA-
BSA (88 mol% PVA), biotin-BSA (88 mol% PVA), PLGA-
BSA (98 mol% PVA), and biotin-BSA (98 mol% PVA) is
calculated as 2.68%, 4.05%, 2.37%, and 4.55%, respectively.
As shown in Figure 5, the model predicts that more BSA is
released by the plain PLGA microparticles than the biotiny-
lated PLGA microparticles, and that PLGA microparticles
made of a lower percent of PVA release slightly more BSA.
This is in a good agreement with the trends shown in the
release profiles. A conclusion drawn from these observa-
tions is that the deviation of the model prediction from the
experimental data is within a reasonably small scale, and
that values of parameters Dd , kd, φ
burst












88 PLGA BSa 1.5 × 10−13 0.03 7.60 0.25
Biotin BSA 9.87 × 10−14 0.16 8.10 0.25
98 PLGA BSa 1.38 × 10−13 0.28 8.63 0.25
Biotin BSA 8.37 × 10−14 0.22 8.50 0.25
Values of the mass fraction of drug involved in the burst phase (φburstd ), drug
desorption rate constant (kd), effective drug diffusivity ( Dd ), and drug
induction time (td) are determined from the drug release profiles.from release profiles properly characterize the drug release
dynamics of all microparticles under investigation.
Table 3 shows the corresponding estimated values of
parameters Dd , kd, φ
burst
d , and td. It can be seen from
Table 3 that Dd decreases by a factor of 0.65 when
microparticles made of 88 mol% PVA were biotinylated.
A similar decreasing ratio (i.e., 0.61) is observed in the
value of Dd for biotinylated microparticles that are made
of 98 mol% PVA. This means that the attachment of
biotin to microparticles slightly slows down the drug
diffusion and thus the drug release process. This is
expected since the presence of the biotin on the outer
surface acts as another layer of diffusion barrier. The
value of Dd decreases by a factor of approximately 0.90
when 98 mol% PVA instead of 88 mol% PVA is used to
make microparticles. This implies that increasing the
mole percentage of PVA can slightly slow down drug re-
lease but to a limited degree. The decrease in drug
release at higher mole percentage of PVA may be due to
its tendency to remain on the surface of the particles
even after hardening. In addition to influencing drug
diffusion process, the attachment of biotin and the mole
percentage of PVA also affect drug release in the burst
phase, in which proteins are desorbed from the outer sur-
face of microparticles. Table 3 shows that the attachment of
biotin reduces the value of φd
burst, the mass fraction of drug
that is desorbed during the burst stage. The authors believe
this is due to the fact that the attachment of biotin reduces
the amount of BSA trapped on the surface during forma-
tion due to steric hindrance. Since the attachment of biotin
cannot change the desorption pattern of proteins from the
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stant (kd) and drug induction time (td). It can also be seen
from Table 3 that the mole percentage of PVA has a minor
effect on protein desorption during the burst phase. This
result, along with the result that the increasing mol% of
PVA did not have a drastic effect on the drug loading and/
or particle morphology, indicates that the higher mole per-
centage of PVA is not providing a more stable emulsion
during the solvent hardening stage of microparticle syn-
thesis. This also indicates that the increase in PVA mole
percentage does not improve the emulsion process, since it
cannot guarantee that more of the drug will remain within
the microparticle during encapsulation.
Conclusions
Polymeric microparticles created through a water-in-
oil-in-water double emulsion effectively demonstrated a
controlled release of a model drug. The presence of
biotin on the outside of the polymeric microparticles
was confirmed using fluorescent imaging. The micro-
particle synthesis was optimized through the use of PVA
consisting of various mole percentages. The effect of the
different PVA surfactant on microparticle synthesis deter-
mined that 88 and 98 mol% PVA created similar particles
that only differed in size and slightly (approximately 10%)
in encapsulation. It was determined that increasing the
mole percentage of PVA created a more stable emulsion
during the hardening phase, allowing for higher encapsu-
lation efficiencies of the model drug (BSA). The release
studies found that the attachment of biotin to the PLGA
microparticle had only a minor effect on the release trend
during the 28-day period. The microparticles still exhibited
a controlled release over the 28 days with minimal burst
and, therefore, are still believed to be effective as carriers
for therapeutic drugs. A release kinetics model was used to
further quantify the effective drug diffusivity and drug
desorption rate, revealing that the attachment of biotin to
microparticles slowed down both drug desorption and drug
diffusion processes, while the mole percentage of PVA only
has a minor effect on drug release rate.
The presence of the biotin on the microparticle, overall,
did not have a negative effect on the microparticles ability
to entrap and control the release of the model drug. This
indicates that the microparticles can be further investi-
gated for their ability to target using a moiety specific to
breast cancer (or other types). This moiety will be
attached to avidin and combined with the microparticle
using the biotin exposed on the microparticle’s surface.
Until that specific moiety is identified, the effect of the
avidin-targeting moiety on the microparticle cannot be
evaluated. The authors believe that this robust linkage
system will be valuable compared to other targeting
strategies, since the simple chemistry will allow for linkage
of a variety of different moieties. Therefore, the sametechnology as well as the proposed integrated experimental
and modeling approach can be used to target either
multiple types of cancer cells, or to include multiple
targeting antigens for the same cell on one microparticle.
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